Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates — Negative
CGC Zacks Investment Research — August 08, 2025Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.37 per share a year ago.
CPI Card Group Inc. (PMTS) Lags Q2 Earnings and Revenue Estimates — Negative
PMTS Zacks Investment Research — August 08, 2025CPI Card Group Inc. (PMTS) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.51 per share a year ago.
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates — Positive
SRDX Zacks Investment Research — August 08, 2025SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
AMC Networks (AMCX) Tops Q2 Earnings and Revenue Estimates — Positive
AMCX Zacks Investment Research — August 08, 2025AMC Networks (AMCX) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $1.24 per share a year ago.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons — Neutral
NVO GlobeNewsWire — August 08, 2025Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Top 2 Materials Stocks That May Fall Off A Cliff In August — Negative
HL MP Benzinga — August 08, 2025As of Aug. 8, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Bain Capital Specialty Finance: I Remain Bullish After Q2 Report — Positive
BCSF Seeking Alpha — August 08, 2025Bain Capital Specialty Finance has issued a solid Q2 report, triggering a positive reaction by the market. This validates my thesis on BCSF - i.e., tangible discount and strongly covered dividend should likely warrant an upside or at least protected downside. In the article, I discuss why, after digesting the Q2 report, I still remain bullish on BCSF.
DENTSPLY SIRONA Inc. (XRAY) Q2 2025 Earnings Call Transcript — Neutral
XRAY Seeking Alpha — August 08, 2025DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Daniel T. Scavilla - President, CEO & Director Matthew E.
Enovix Establishes R&D Center of Excellence in India to Accelerate AI-2™ Platform Development — Neutral
ENVX GlobeNewsWire — August 08, 2025FREMONT, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX) (“Company” or “Enovix”), a global high-performance battery company, today announced that it has created an R&D Center of Excellence in Hyderabad, India to accelerate the development of its Artificial Intelligence Class TM second-generation battery platform AI-2 TM into 2025.
Dividend Cut Alert: 2 BDCs With Unsustainable Yields — Negative
FSK OCSL Seeking Alpha — August 08, 2025BDC sector faces significant risks: high valuations, spread tightening, and thin dividend coverage leave little margin of safety. Lower base rates will likely be soon here, creating further headwinds for BDCs and pressuring net investment income and dividends. I recommend avoiding speculative BDCs, focusing on high-quality names with robust portfolios and strong dividend coverage at a discount.
With just a passing glance at its recent results, it would be easy to presume the worst of retailer Target (TGT -0.70%). Same-store sales fell 3.8% year over year during the first quarter of this year, extending a string of lackluster numbers going all the way back to 2023.
After Strong Q2 Beat Sunrun Rises, But Surge May Be Short-Lived — Positive
RUN Seeking Alpha — August 08, 2025Sunrun's Q2 earnings beat expectations, but profitability relies on non-controlling interests absorbing unsustainable losses, raising long-term sustainability concerns. Operating cash flow remains negative, with growth fueled by increasing debt and external funding rather than true business improvement. The business model is heavily dependent on tax incentives, particularly 48E, which begin phasing out in 2028, casting doubt on future viability.
Terreno Realty Corporation Sells Property in Santa Fe Springs, CA for $11.0 Million — Neutral
TRNO Business Wire — August 08, 2025BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation Sells Property in Santa Fe Springs, CA for $11.0 Million.
FatPipe Inc. Ranked #1 for Product and #1 for Support in Info-Tech Research Group's 2025 SD-WAN Midmarket Report — Neutral
FATN Accesswire — August 08, 2025SALT LAKE CITY, UT / ACCESS Newswire / August 8, 2025 / FatPipe, Inc. (NASDAQ:FATN) ("FatPipe" or the "Company"), a pioneer in enterprise-class, application-aware, secure software-defined wide area network ("SD-WAN") solutions that provide the highest levels of reliability, security, and optimization for Wide Area Networks (WANs) is pleased to announce that the global research and advisory firm, Info-Tech Research Group, has identified FatPipe Inc. #1 for Product and #1 for Support in its 2025 SD-WAN Midmarket Report . The report findings are based on data from user reviews on the firm's SoftwareReviews platform, the leading source for insights on the …
Apple's Tremendous Lead in Global Smartphone Revenue — Neutral
AAPL 24/7 Wall Street — August 08, 2025Most public measurements of smartphone sales data focus on unit sales. In every quarter in memory, Apple Inc.
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference — Neutral
ANIX PRNewsWire — August 08, 2025Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif. , Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, virtually and in-person at the Briar Club in Houston, Texas.
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results — Negative
HAE Benzinga — August 08, 2025Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.
Goldman Sachs turns bullish on Peloton after strong Q4 results, sees 61% upside — Positive
PTON Invezz — August 08, 2025Goldman Sachs has upgraded its outlook on Peloton (PTON) following stronger-than-expected quarterly earnings that eased investor concerns and signaled a potential turnaround for the connected fitness company.
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript — Neutral
RGNX Seeking Alpha — August 08, 2025REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.
Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal -- Hagens Berman — Neutral
SLP GlobeNewsWire — August 08, 2025SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Investors in Simulations Plus, Inc. (NASDAQ: SLP) saw the price of their shares decline about 25% on July 15, 2025 after the company reported its Q3 2025 $67.3 million net loss that included a $77.2 million impairment charge and the company's firing of its independent auditor Grant Thornton, whom it hired on April 15, 2025. Simulations Plus's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether the company may have misled investors about its asset valuations and the reasons why it abruptly dismissed Grant Thornton and …